Trulicity ® (dulaglutide) injection

0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

When starting Trulicity® (dulaglutide): can patients continue taking sulfonylureas or insulin?

Consider reducing insulin/insulin secretagogue dose when initiating Trulicity (dulaglutide).

Detailed Information

Concomitant Use With an Insulin Secretagogue or With Insulin

To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered

  • insulin secretagogues, such as sulfonylureas, or

  • insulin.1

Enclosed Prescribing Information

TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly

Reference

1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Date of Last Review: September 10, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical